Vapotherm Inc (NYSE:VAPO) saw a significant growth in short interest in June. As of June 30th, there was short interest totalling 284,800 shares, a growth of 27.5% from the May 30th total of 223,300 shares. Currently, 3.4% of the shares of the company are short sold. Based on an average daily trading volume, of 43,500 shares, the short-interest ratio is currently 6.5 days.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VAPO. Pura Vida Investments LLC purchased a new stake in shares of Vapotherm during the fourth quarter worth about $2,984,000. BlackRock Inc. purchased a new stake in shares of Vapotherm during the fourth quarter worth about $6,248,000. Lord Abbett & CO. LLC purchased a new stake in shares of Vapotherm during the fourth quarter worth about $7,573,000. Northern Trust Corp purchased a new stake in shares of Vapotherm during the fourth quarter worth about $1,156,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Vapotherm during the fourth quarter worth about $118,000. 46.91% of the stock is owned by institutional investors.
VAPO opened at $20.36 on Friday. Vapotherm has a fifty-two week low of $14.70 and a fifty-two week high of $24.63. The company has a debt-to-equity ratio of 1.01, a current ratio of 6.35 and a quick ratio of 5.34. The firm has a fifty day moving average price of $19.62.
Vapotherm (NYSE:VAPO) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.03. The firm had revenue of $12.30 million during the quarter, compared to analysts’ expectations of $11.90 million. As a group, equities analysts anticipate that Vapotherm will post -3.15 EPS for the current year.
Separately, Zacks Investment Research cut shares of Zai Lab from a “buy” rating to a “hold” rating in a report on Saturday, June 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $26.50.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.